STOCK TITAN

Maxcyte - MXCT STOCK NEWS

Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.

MaxCyte, Inc. (MXCT) pioneers advanced cell engineering through its proprietary Flow Electroporation technology, enabling breakthroughs in gene therapy and biopharmaceutical development. This dedicated news hub provides investors and industry professionals with essential updates on MXCT’s strategic initiatives, financial performance, and scientific advancements.

Access timely press releases covering regulatory milestones, partnership announcements, and technology innovations. Our curated collection includes earnings reports, clinical trial updates, and analyses of MXCT’s role in advancing next-generation cell therapies. The platform serves as a critical resource for tracking the company’s impact on precision medicine and scalable therapeutic manufacturing.

Discover updates about MXCT’s ExPERT platform deployments, licensing agreements with biotech innovators, and expansions in global research collaborations. Content is organized for quick scanning while maintaining technical accuracy, ensuring relevance for both casual observers and specialized analysts.

Bookmark this page for streamlined access to verified MXCT developments. Combine our news feed with Stock Titan’s financial tools to monitor how MaxCyte’s cell engineering leadership translates into long-term market positioning.

Rhea-AI Summary

MaxCyte has appointed Cenk Sumen, Ph.D., as the new Chief Scientific Officer (CSO), effective March 9, 2022. Dr. Sumen brings a wealth of experience in scientific innovation and technology development, having previously served as CTO at Stemson Therapeutics. MaxCyte is a pioneering cell-engineering company dedicated to advancing cell-based research and therapies with its Flow Electroporation® technology. CEO Doug Doerfler expressed enthusiasm for Dr. Sumen's strategic vision, which aims to enhance MaxCyte’s position in the growing cell therapy market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
none
-
Rhea-AI Summary

MaxCyte, Inc. (NASDAQ: MXCT) will release its fourth quarter and full year 2021 financial results on March 22, 2022, after U.S. market close. A conference call is scheduled for 4:30 p.m. Eastern Time to discuss the results. The company, recognized for its proprietary Flow Electroporation® platform, is focused on advancing cell-based research and the cell therapy market with its ExPERT™ platform. This technology supports various stages of cell therapeutic development and commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
conferences earnings
-
Rhea-AI Summary

MaxCyte, a leader in cell-engineering technology, announced its participation in several upcoming virtual investor conferences. Key events include the BIO CEO & Investor Conference on February 15, the BTIG MedTech event on February 17 at 3:00 p.m. ET, and the Cowen Annual Healthcare Conference on March 7 at 9:50 a.m. ET. The company will provide live and archived webcasts of these presentations on its investor relations website. MaxCyte's technologies aim to enhance cell-based research and support the growing cell therapy market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
conferences
Rhea-AI Summary

MaxCyte, a commercial cell-engineering company, has granted stock options for 204,500 shares to eight new employees as part of its 2021 Inducement Plan. This move, effective from February 10, 2022, aligns with Nasdaq rules and aims to incentivize talent acquisition. Each option has a ten-year term with an exercise price of $6.54, matching the stock's closing price on the grant date. Vesting occurs over four years, with 25% available after the first year. This initiative underscores MaxCyte's commitment to enhancing its workforce to drive next-generation cell-based medicine advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
none
-
Rhea-AI Summary

MaxCyte has signed a strategic platform license with Intima Bioscience, a biotechnology company focused on cell therapies for solid tumors. This agreement grants Intima access to MaxCyte’s Flow Electroporation® technology and ExPERT™ platform, aimed at enhancing the development of its checkpoint cell therapy targeting CISH in gastrointestinal and colon cancers. MaxCyte will receive licensing fees and milestone payments from Intima. This partnership marks MaxCyte's 16th such collaboration, further expanding its technology's application in the cell therapy market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
Rhea-AI Summary

MaxCyte, Inc. (NASDAQ: MXCT) expects fourth quarter 2021 revenue to exceed $10 million, up 17% from Q4 2020, with full year revenue anticipated above $33.7 million, marking a 28% increase from 2020. The company reports over 500 instruments installed and 15 Strategic Platform Licenses (SPLs), enabling over 95 programs, with 15% in clinical stages. MaxCyte's SPLs could lead to over $1.25 billion in precommercial revenue potential. CEO Doug Doerfler highlighted significant achievements in 2021, including a successful IPO and organic growth in core business.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
none
Rhea-AI Summary

MaxCyte, a commercial cell-engineering company, announced its participation in several investor conferences. The events include the Consilium Strategic Communications 9th Annual Healthcare Conference on November 15, 2021, Stifel 2021 Virtual Healthcare Conference on November 16, and Stephens Annual Investment Conference on November 29. Each session will feature discussions led by company management. Live and archived webcasts will be available on MaxCyte's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
conferences
-
Rhea-AI Summary

MaxCyte reported a strong third quarter for 2021 with total revenue of $10.1 million, reflecting a 50% increase compared to Q3 2020. Revenue from cell therapy customers rose 38% to $6.2 million, while Strategic Platform License (SPL) revenue reached a record $2.0 million. Operating expenses increased to $11.6 million, primarily due to higher compensation and professional service costs. The company projects at least $33.0 million in revenue for FY 2021, up from earlier guidance of $30 million. Net loss for Q3 was ($2.7) million compared to ($3.1) million in 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.37%
Tags
-
Rhea-AI Summary

MaxCyte, a leader in cell-engineering, announces the appointment of Richard Douglas, PhD, as Chair of the Board, succeeding J. Stark Thompson, PhD, who will remain a consultant. Douglas, a board member since 2018, brings extensive experience from roles at RedSky Partners, Aldeyra Therapeutics, and Novavax. His leadership follows a pivotal period marked by the company's first U.S. public offering. CEO Doug Doerfler praised Douglas for his valuable contributions and the foundation laid by Thompson, emphasizing the company’s strong position in the expanding cell therapy market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
management
News
Rhea-AI Summary

MaxCyte, a leader in cell-engineering, announced that all resolutions at its Annual General Meeting on October 29, 2021, were passed, except for Proposal 2 concerning the 2021 Equity Incentive Plan. The company focuses on advancing cell-based research and next-generation cell therapies through its proprietary Flow Electroporation® platform, which supports the expansive cell therapy market. MaxCyte's ExPERT™ platform includes a range of instruments and software aimed at facilitating the development of innovative cell-based medicines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
none
Maxcyte

Nasdaq:MXCT

MXCT Rankings

MXCT Stock Data

270.37M
99.48M
1.49%
74.25%
2.56%
Medical Devices
Services-commercial Physical & Biological Research
Link
United States
ROCKVILLE